Compare · AORT vs MDLN
AORT vs MDLN
Side-by-side comparison of Artivion Inc. (AORT) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AORT and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 36.4x AORT ($1.29B).
- MDLN has been more active in the news (12 items in the past 4 weeks vs 8 for AORT).
- MDLN has more recent analyst coverage (25 ratings vs 8 for AORT).
- Company
- Artivion Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $1.29B
- $46.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 8
- 12
- Recent ratings
- 8
- 25
Artivion Inc.
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Latest AORT
- President & CEO Mackin James P sold $2,026,850 worth of shares (70,000 units at $28.95), decreasing direct ownership by 7% to 877,275 units (SEC Form 4)
- SVP, Regulatory and Quality Green Andrew M sold $17,586 worth of shares (616 units at $28.55), decreasing direct ownership by 1% to 59,643 units (SEC Form 4) to satisfy withholding tax
- EVP, COO, CFO & Treasurer Berry Lance A sold $20,413 worth of shares (715 units at $28.55), decreasing direct ownership by 0.34% to 210,112 units (SEC Form 4) (tax liability)
- SVP, General Counsel Holloway Jean F sold $27,835 worth of shares (977 units at $28.49), decreasing direct ownership by 0.53% to 184,118 units (SEC Form 4)
- SEC Form 10-Q filed by Artivion Inc.
- Artivion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Artivion Reports Second Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Artivion Inc.
- Artivion to Participate in Upcoming Investor Conferences
- Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.